A nationwide multi-institutional retrospective study to examine predictors of early postoperative recurrence in anatomically resectable pancreatic cancer treated with neoadjuvant chemotherapy (NAC-GS) (NAC-PIONEER trial)

A nationwide multi-institutional retrospective study to examine predictors of early postoperative recurrence in anatomically resectable pancreatic cancer treated with neoadjuvant chemotherapy (NAC-GS) - NAC-PIONEER trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058482

Enrollment

5500

Registered

2025-08-01

Start date

2025-08-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resectable pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Invasive pancreatic ductal adenocarcinoma Resectable pancreatic cancer Cases of initial treatment with NAC-GS Cases with measurable lesions

Exclusion criteria

Exclusion criteria: Cases in which NAC was introduced with a regimen other than GS Patients who could not undergo contrast-enhanced CT imaging due to allergy Patients who refused to participate in this study by opting out

Design outcomes

Primary

Measure	Time frame
Percentage of recurrence within 6 months after surgery among patients with anatomically resectable pancreatic cancer who underwent radical resection after NAC-GS	—

Secondary

Measure	Time frame
Recurrence-free survival rate Cumulative recurrence rate Overall survival rate Site of recurrence Form of recurrence Exploration of factors involved in early recurrence	—

Countries

Japan

Contacts

Public ContactYuuko Tohmatsu

University of Toyama Department of Surgery and Science, Faculty of Medicine, Academic Assembly,

yuukot@med.u-toyama.ac.jp076-434-7331

Outcome results